Latest Content

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.

In a post hoc indirect comparison, data showed zanubrutinib was linked with improved PFS vs acalabrutinib/venetoclax in treatment-naive CLL.

Read our recap of top phase 3 breast cancer data announcements and highlights that may influence clinical practice in the near future.

Neoadjuvant anbenitamab plus albumin-bound docetaxel yielded a significant tpCR benefit vs standard therapy in HER2-positive early breast cancer.

A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy.

Jeremy Kortmansky, MD, discusses early-onset CRC, the importance of molecular profiling, and emerging therapeutic targets in this clinician-focused FAQ.

C. Ola Landgren, MD, PhD, discusses the development of the AI risk-stratification model CORAL and its potential role in individualizing myeloma care.

Cemiplimab plus chemotherapy produced variable outcomes by genomic profile in patients with nonsquamous NSCLC.

Neil Mendhiratta, MD, MS, discusses the treatment landscape for patients with kidney cancer during Kidney Cancer Awareness Month.

An NDA for lirafugratinib in pretreated, FGFR2-altered cholangiocarcinoma was accepted for FDA review and assigned a PDUFA date of September 27, 2026.

6-year Roswell Park study shows shorter, lower-dose approach works just as well as longer course of treatment

The biosimilar Ponlimsi is approved for all reference denosumab indications, and applications for an omalizumab biosimilar candidate have been accepted.

Michael J. Mauro, MD, discusses the variety of TKIs available for chronic myeloid leukemia management and how to navigate new formulations.